Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ArthroCare cleared by SEC

This article was originally published in The Gray Sheet

Executive Summary

The Securities & Exchange Commission says in a May 29 letter that it does not intend to recommend enforcement action against ArthroCare following a probe into the firm's stock-option practices. SEC asked to review ArthroCare's financial information in August as part of a widespread investigation into potential options abuses at scores of companies (1"The Gray Sheet" Aug. 28, 2006, In Brief)...

You may also be interested in...

SEC targets ArthroCare

Bank of America Equity Research analyst Steven Lichtman tells investors Aug. 24 that his group found "no unusual patterns in the timing or pricing of options and no evidence of backdating" in its review of ArthroCare documents. The previous day, the U.S. Securities & Exchange Commission asked to review information about ArthroCare's stock option grant practices. "We see no reason at this point to believe that filing delays or financial restatements are imminent," Lichtman wrote in a research brief...

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts